ClinTec International starts operations in Malawi

Published: 30-Jul-2012
Research & Development Pharmaceutical

Leading pharmaceutical company selects ClinTec as partner of choice in Africa and Asia


ClinTec International, a global contract research organisation (CRO) with a substantial presence in the Middle East and Africa, has expanded its operations into Malawi.

A pharmaceutical company with sales exceeding US$50bn has chosen the firm as its preferred partner for vaccine development in Africa and Asia.

ClinTec is recruiting skilled personnel with vaccine research experience to join its established teams in these regions, in preparation for anticipated strong growth ahead.

ClinTec operates in more than 40 countries to provide specialist clinical research personnel and support services.

Rabinder Buttar, president and ceo of ClinTec, said: ‘I see huge potential for the company in conducting large-scale vaccine trials. Despite the challenging economic conditions through which many of our clients are restructuring their organisations, ClinTec continues to grow and win major new business from pharma companies.’

  • Companies:
  • ClinTec International
See more

You may also like

Regulatory

Clintec secures Queen’s Award for Enterprise – International Trade

Read more
This is the second time the company has won the accolade, which recognises breadth and diversity of global capabilities

Trending Articles

  1. Sartorius Stedim Biotech supports bioprocess development with new Innovation Centre The Massachusetts, US-based Centre for Bioprocess Innovation is a collaborative space designed to develop and optimise biomanufacturing processes
  2. Aurobindo Pharma signs $25m respiratory drug development and commercialisation deal with global pharma company The companies will co-develop and commercialise respiratory therapeutics, diversifying Aurobindo's current portfolio
  3. Steritas and argenx join forces to advance steroid-sparing therapeutic development With the help of Steritas' STOX Suite, argenx aims to develop antibody-based therapeutics for immune diseases, potentially allowing patients to move away from chronic steroid usage
  4. Merck's Welireg approved for cancers associated with von Hippel-Lindau disease in China The once-daily drug is the first HIF-2α to be approved in China, exhibiting a 49% objective response rate (ORR)

Upcoming event

CPhI Middle East

10–12 December 2024 | Conference | Riyadh, Saudi Arabia See all

You may also like

Regulatory

Clintec secures Queen’s Award for Enterprise – International Trade

This is the second time the company has won the accolade, which recognises breadth and diversity of global capabilities
Research & Development

Clintec launches new brand and website

Clintec announces the launch of its new brand identity reflected in a newly created website, to mark their 20th year of global clinical research
Training & Education

ATC endorses Clintec International and Edinburgh Napier University Masters programme

Programme launched last year to support the development of clinical research staff throughout the world
Research & Development

ClinTec International opens office in Istanbul

Further expanding in the Middle East and North Africa
Research & Development

ClinTec expands into China, Singapore and Thailand

Increases presence in emerging markets
Research & Development

ClinTec International expands US capabilities

Appoints associate director of US Business Operations in New York
Training & Education

ClinTec opens training academy in Dubai

To focus on training clinical researchers in emerging markets
Subscribe now